Axsome Therapeutics, Inc.
AXSM
|
$68.21
-1.36%
-1.3%
430K
|
Health Technology
(0.0% 1d) (-6.0% 1m) (-3.2% 1y) (0.0% 2d) (0.0% 3d) (-3.9% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 3,231,406,119
http://www.axsome.com
Sec Filling | Patents | 45 employees
(US) Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
nervous system
add to watch list Paper trade email alert is off
Press-releases
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: -3.37%
H: 0.83%
C: -0.76%
neurology meeting therapeutics
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: -2.66%
H: 1.26%
C: 0.37%
first report therapeutics financial results
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy therapeutics results
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: -0.45%
H: 0.86%
C: -1.58%
conference biopharma global therapeutics
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 0.75%
H: 2.12%
C: 1.3%
conference therapeutics
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: -8.42%
H: 3.52%
C: -4.54%
business year update therapeutics financial results
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
AXSM | $68.21 -1.36% -1.3% 430K
|
Health Technology
|
| O: 0.62%
H: 0.43%
C: -2.14%
report year therapeutics financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Last 48 Hours Insiders Buying
RMCF | $3.6492 2.51% -7.2% 7.1K
|
Consumer Non-Durables
|
20:10